Beijing, China

Yuelei Shen

USPTO Granted Patents = 45 

 

Average Co-Inventor Count = 5.6

ph-index = 2

Forward Citations = 24(Granted Patents)


Company Filing History:


Years Active: 2019-2025

where 'Filed Patents' based on already Granted Patents

45 patents (USPTO):

Title: Innovations in Cancer Treatment by Yuelei Shen

Introduction

Yuelei Shen, a prominent inventor based in Beijing, China, has made significant contributions to the field of oncology through his innovative research and development. With an impressive portfolio of 44 patents, Shen is dedicated to advancing medical treatments that enhance patient outcomes and tackle complex diseases such as cancer.

Latest Patents

Among Shen's latest patents are groundbreaking discoveries regarding anti-PD-1 antibodies and anti-CD40 antibodies. His patent related to anti-PD-1 antibodies outlines novel methods of treating cancer by targeting the Programmed Cell Death Protein 1, a critical component in the regulation of immune responses. Additionally, his work on anti-CD40 antibodies involves innovative approaches to harness the immune system in combating tumors, demonstrating his commitment to developing effective cancer therapies.

Career Highlights

Yuelei Shen has an impressive career marked by his tenure at well-respected organizations. He has worked with Biocytogen Pharmaceuticals (Beijing) Co., Ltd. and Eucure (Beijing) Biopharma Co., Ltd., where he played pivotal roles in research and development. His experience in these companies has allowed him to refine his expertise in biopharmaceutical innovations, particularly in antibody development for cancer treatment.

Collaborations

Throughout his career, Shen has collaborated with esteemed colleagues in the field, including Yanan Guo and Yang Bai. These partnerships have contributed to the successful translation of research into practical applications, ensuring that cutting-edge therapies reach those in need.

Conclusion

Yuelei Shen's contributions to the medical field, particularly in oncology, underscore his role as a leading inventor. With a strong focus on developing innovative treatments such as anti-PD-1 and anti-CD40 antibodies, Shen continues to make strides that could potentially change the landscape of cancer therapy, emphasizing the importance of research and collaboration in the pursuit of healthcare advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…